問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Cardiovascular Diseases

Division of Neurology

更新時間：2023-09-19

李任光LEE, JEN-KUANG
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李任光

List

43Cases

2025-10-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2023-09-01 - 2027-07-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2019-01-02 - 2021-12-31

Others

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Recruiting1Sites

2023-12-15 - 2028-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

  • Condition/Disease

    Transthyretin amyloid cardiomyopathy

  • Test Drug

    ALXN2220

Participate Sites
5Sites

Recruiting5Sites

2014-02-01 - 2019-01-25

Phase III

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    BRILINTA

Participate Sites
25Sites

Recruiting1Sites

Terminated24Sites

2017-02-01 - 2019-05-09

Phase III

Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement. (EdoxabaN Treatment versus VKA in patients with AF undergoing PCI ( ENTRUST-AF PCI)

  • Condition/Disease

    Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement

  • Test Drug

    Edoxaban (DU-176b)

Participate Sites
13Sites

Terminated11Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2015-06-01 - 2016-12-31

Phase III

A Phase III Prospective, Randomized, Double Blind, Active Controlled, Multicenter, Parallel Group Study to Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients with Intermittent Claudication

  • Condition/Disease

    Intermittent Claudication

  • Test Drug

    PMR

Participate Sites
6Sites

Terminated6Sites

2016-10-26 - 2020-12-31

Phase III

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, MultiCenter Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

  • Condition/Disease

    Heart Failure With Reduced Ejection Fraction (HFrEF)

  • Test Drug

    MK-1242 (vericiguat)

Participate Sites
6Sites

Terminated6Sites

江晨恩
Taipei Veterans General Hospital

2019-12-01 - 2020-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

  • Condition/Disease

    Drug-Resistant Epilepsy/Focal-Onset Seizures

  • Test Drug

    Padsevonil

Participate Sites
8Sites

Terminated8Sites

2016-11-01 - 2021-04-10

Phase III

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction

  • Condition/Disease

    acute myocardial infarction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Not yet recruiting2Sites

Terminated7Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB